ImClone expected to get Erbitux approved by FDA this time

02/11/2004 | NYTimes.com

The drug that was rejected by the FDA, sparking a Wall Street scandal, is back before the agency for approval, with ImClone Systems making a new effort to get the agency's OK for its cancer drug. Analysts believe better clinical trial data are available this time, and the FDA is expected to give its approval before the deadline for a decision expires this week.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Director of Operations - GBS
Mayo Clinic
Rochester, MN
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Senior Vice President, Clinical Affairs & Strategic Partnerships
America's Health Insurance Plans (AHIP)
Washington, DC